Author: Ravi Shankar

– In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis

– Acoramidis was also associated with a significant 43% reduction in risk of diuretic intensification versus tafamidis (p=0.021); diuretic intensification is an early marker of worsening heart failure and worse clinical outcomes

– Separation in clinical outcomes emerged within weeks of treatment initiation and increased over time, reinforcing a consistent early treatment effect and durable clinical stabilization

– Findings underscore acoramidis’s differentiated profile, with potential to inform frontline treatment decisions and support switching individuals to acoramidis

– An additional, independent real-world study evaluating the effectiveness of acoramidis versus tafamidis using electronic health records data is expected to be released at an upcoming 2026 medical meeting

PALO ALTO, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced results published in Cardiology and Therapy from the first peer-reviewed, contemporary real-world comparative effectiveness retrospective study of transthyretin (TTR) stabilizers in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrating that acoramidis was associated with significantly lower risk of early clinical worsening compared to tafamidis. This represents the first peer-reviewed, real-world evidence differentiating clinical outcomes between approved TTR stabilizers, reinforcing acoramidis’s differentiated clinical profile in present-day practice.

“These findings further position acoramidis as a differentiated TTR stabilizer in contemporary clinical practice,” said Richard Wright, M.D., M.A.C.C. of the Pacific Heart Institute, U.S. “The significant reduction in diuretic intensification, an early indicator of worsening heart failure, points to improved disease control and clinical stability. The progressive nature of ATTR-CM is evident in all Phase 3 trials and is seen again here. This demonstrates the need for clinicians to proactively mitigate disease progression, and these data have the potential to meaningfully inform treatment selection in newly diagnosed patients and in patients currently on other treatments.”

In this analysis of newly treated individuals living with ATTR-CM, acoramidis showed early, consistent, and clinically meaningful advantages compared to tafamidis across key measures of disease progression during a mean follow-up of 4.6 months.

The key findings from the study comparing acoramidis benefit versus tafamidis in individuals with ATTR-CM:

• 34% statistically and clinically significant reduction in risk of composite clinical worsening (HR 0.66; p=0.046), including diuretic intensification, heart failure hospitalization, and all-cause mortality
• 43% reduction in risk of diuretic intensification (HR 0.57; p=0.021), an established early marker of worsening heart failure and predictor of hospitalization and mortality; diuretic intensification was rigorously defined as initiation or dose-equivalent escalation of oral loop diuretics, parenteral loop diuretics use, or addition of a thiazide-type diuretic
• 48% reduction in initiation or dose-equivalent escalation of oral loop diuretics (HR=0.52; p=0.014)
• Rapid benefit, with separation of Kaplan-Meier curves observed within weeks of treatment initiation and increasing over time
• Fewer individuals with acoramidis initiated alternative ATTR-CM therapy as compared to those treated with tafamidis (4.6% vs 7.7%, respectively), consistent with findings of improved clinical stability with acoramidis
• Background heart failure therapies in this study were well balanced across arms and reflect contemporary practice: 43-44% SGLT2i, 36-39% MRA
• Multiple falsification analyses testing for residual bias were nonsignificant

The study leveraged a retrospective, longitudinal, new-user, active-comparator design using U.S. claims data and incorporated a unique dataset linking Komodo Healthcare Map U.S. claims with Claritas hub and specialty pharmacy data. After weighting, the analysis included 170 individuals with acoramidis and 448 individuals with tafamidis newly initiating treatment between Dec 2024-April 2025 and followed through July 2025, with a mean follow-up of approximately 4.6 months.

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Additional data on the real-world benefit of acoramidis versus tafamidis in individuals living with ATTR-CM is planned for fall medical meetings and scientific publications, including an independent real-world study evaluating the effectiveness of acoramidis versus tafamidis using electronic health records data, expected to be released at an upcoming 2026 medical meeting.

As with all real-world evidence studies, these findings should be interpreted in the context of inherent limitations of administrative claims data, including limited capture of cardiac biomarkers and other clinical measures of disease severity. Follow-up was limited given the recent approval of acoramidis, and longer-term data are needed to further add to these findings.

About Attruby^® (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the real-world data regarding acoramidis, including the potential for the findings to inform frontline treatment decisions and treatment selection for newly diagnosed patients and patients currently receiving other treatments, and to support switching individuals to acoramidis; and BridgeBio’s plans and expectations regarding the presentation and publication of additional real-world data regarding acoramidis, including an independent real-world study evaluating the effectiveness of acoramidis versus tafamidis using electronic health records data expected to be released at an upcoming 2026 medical meeting. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the risk that results from retrospective, observational, real-world evidence studies, including studies based on administrative claims data, may be subject to confounding, selection bias, residual bias, incomplete or inaccurate data, limited follow-up or other limitations and may not be predictive of future clinical outcomes or treatment effects; that the observed associations and differences between acoramidis and tafamidis may not be replicated in additional analyses, independent studies or longer-term data or may not translate into improved long-term clinical outcomes; that the findings may not meaningfully inform treatment selection or support switching patients to acoramidis; that additional real-world studies, including the independent study evaluating the effectiveness of acoramidis versus tafamidis using electronic health records data, may yield results that differ from or do not confirm the findings described in this press release; that plans or timing for future medical meeting presentations or scientific publications may change; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com  
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) is pleased to announce the appointment of Peter Brady as Executive Vice President, General Counsel and Corporate Affairs, effective September 28, 2026.

“I am pleased to welcome Peter to DPM’s executive team. He brings a wealth of strategic legal expertise and proven leadership in navigating the complex regulatory and governance challenges facing the mining industry today,” said David Rae, President and CEO of DPM Metals.

“His track record of building high-performing legal teams, combined with his deep experience in managing significant transactions and providing sound counsel to executive teams, will be invaluable as we advance our strategic priorities.”

Mr. Brady has nearly three decades of legal experience in the global mining and metals sector and private practice, with deep expertise in environmental law, regulatory compliance, corporate governance and complex transactions. Prior to joining DPM, he most recently served as Executive Vice President and General Counsel at Lundin Mining, leading the company’s corporate legal, regulatory and governance matters. Prior to that, he was Chief Legal & Governance Officer with Vale Base Metals, responsible for advising their senior leadership team on all legal and business risk, compliance, and corporate governance matters. Previous to Vale Base Metals, he was a Partner at McCarthy Tetrault, co-leading the National Environmental, Regulatory and Aboriginal Practice.

Mr. Brady holds a Bachelor of Laws from Queen’s University and a Master of Arts in environmental law from the University of Windsor, and is called to the Bar in both Ontario and British Columbia.

About DPM Metals Inc.

DPM Metals Inc. is a Canadian-based international gold mining company with operations and projects located in Bulgaria, Bosnia and Herzegovina, Serbia and Ecuador. Our strategic objective is to become a mid-tier precious metals company, which is based on sustainable, responsible and efficient gold production from our portfolio, the development of quality assets, and maintaining a strong financial position to support growth in mineral reserves and production through disciplined strategic transactions. This strategy creates a platform for robust growth to deliver above-average returns for our shareholders. DPM trades on the Toronto Stock Exchange (symbol: DPM) and the Australian Securities Exchange as a Foreign Exempt Issuer (symbol: DPM).

For further information please contact:

Jennifer Cameron
Director, Investor Relations
Tel: (416) 219-6177
jcameron@dpmmetals.com

VEON increases Share Buyback and Accelerates share cancellations 

Group launches new program to repurchase 3.9% of outstanding shares (2.9 million ADSs), comprising open market repurchases and proportionate shareholder participation

New York and Dubai, September 23, 2026 — VEON Ltd. (Nasdaq: VEON), a global digital operator, today announced a new program to buy back 3.9% of VEON’s outstanding shares (72.5 million shares or equivalent in shares and ADS). This represents a share buyback program of approximately USD 200 million based on a closing price of USD 69.37 per ADS (each ADS represents 25 shares) as of September 22, 2026. The Group also confirms that the first phase of open market repurchases under the new program is underway. VEON will cancel all shares acquired under the new buyback program, reinforcing its commitment to disciplined capital allocation and long-term value creation.

Assuming a share repurchase of USD 200 million based on an ADS price of USD 69.37, the new program represents 27.5% of VEON’s trailing-twelve-month Equity Free Cash Flow, after leases and licenses, for the period ended June 30, 2026, and a 5.5% yield based on the average closing price of VEON stock over the trailing twelve months as of September 22, 2026. The final value of the buy-back program will vary with the price per share or ADS purchased. The new program upgrades the minimum USD 100 million annual buyback target announced in May 2025 and is in addition to the USD 100 million program announced in November 2025 which has been completed. The revised policy places recurring capital returns at the heart of VEON’s capital allocation framework, alongside investment in profitable growth and maintaining financial flexibility.

 “Returning cash to shareholders is a core priority for VEON,” said Kaan Terzioglu, Group CEO of VEON. “Having completed USD 200 million in cumulative buybacks since August 2024, we are increasing our annual repurchase program to 3.9% of outstanding shares, which at today’s price represents approximately USD 200 million. Our focus is clear: grow cash flow, invest with discipline and translate our operating performance into greater value per share.”

Including earlier phases of the program first announced in August 2024, VEON has now repurchased 4.46 million ADSs (6.0% of total ADSs outstanding) for a total consideration of USD 227.6 million. After giving effect to shares issuance in March 2024 and subsequent transfers, shares and ADSs held by VEON represent approximately 7.9% of total outstanding shares.

The new program will comprise open market repurchases and direct repurchases of shares from VEON’s shareholder LetterOne, which has agreed to sell proportionally to its existing shareholding and accordingly to sell to VEON up to 32,957,830 shares, at prices and volumes determined by reference to the open market repurchases.

The new program repurchases will be conducted within the parameters of VEON’s broader securities repurchase program and in accordance with applicable laws and regulations. 

About VEON
VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity and more than 228 million digital customers. Operating across five countries that are home to 550 million consumers, more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

Forward-Looking Statements
This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to the execution and/or impact of the buyback of the VEON Group’s ADSs and shares and the cancellation of such shares. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to uncertainty over the execution and/or impact of the buyback of the VEON Group’s ADSs and shares, among others discussed in the section entitled “Risk Factors” in VEON’s 2025 Form 20-F filed with the SEC on March 16, 2026 and other public filings made by VEON with the SEC. There is no assurance that the buyback of VEON ADSs and shares and the cancellation of such shares will be completed or that other events described in any forward-looking statement will materialize. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

Contact Information
VEON
ir@veon.com

EDEN PRAIRIE, Minn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, plans to issue its fourth quarter and fiscal 2026 financial results before the opening of the New York Stock Exchange on Wednesday, October 21, 2026. At 9:00 a.m. CT, the Company will conduct a conference call hosted by Michael Happe, president and chief executive officer, and Bryan Hughes, senior vice president and chief financial officer.

You are invited to listen to the call via the “Investors” section of the Company’s website, https://www.winnebagoind.com/investors. The event will be archived and available for replay for up to one year. To access the replay, visit https://winnebago.gcs-web.com/event-calendar.

About Winnebago Industries 

Winnebago Industries, Inc. is a leading North American manufacturer of outdoor recreation products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota, and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries’ investor relations materials, visit www.winnebagoind.com/investors.

Contacts 

Investors: Joan Ondala ir@winnebagoind.com

Media: Daniel Sullivan media@winnebagoind.com

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030

New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group

SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. The application covers ART27.13 both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic^® and Wegovy^®.

The filing follows unexpected findings from Artelo’s nonclinical DIO-2 study that point to a potentially broader role for ART27.13 in weight and metabolic regulation. The Company is disclosing additional findings from the study today, alongside results reported on September 16, 2026.

As previously reported, ART27.13 monotherapy produced approximately 20% weight loss from baseline over four weeks in obese mice, comparable to semaglutide. In combination with semaglutide, obese mice lost approximately 40% of their baseline body weight. Approximately 80% of the weight lost in ART27.13-treated groups was fat, compared with approximately 70% with semaglutide alone.

The new findings show that the combination suppressed appetite more than semaglutide alone and further improved oral glucose tolerance. Bone mineral density increased in the combination group, an effect not observed in any other treatment group. Semaglutide and ART27.13 each reduced total cholesterol, LDL and HDL to similar extents, with greater reductions when given together. Liver hypertrophy was reduced across all treatment groups.

“These findings were unexpected and potentially expand the opportunity for ART27.13 well beyond our original hypothesis,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We began studying ART27.13 alongside semaglutide because our published cancer cachexia research with Professor Richard Porter of Trinity College Dublin indicated it helps preserve muscle. We observed substantial weight loss with ART27.13 on its own, an approximate doubling of weight loss in combination with a semaglutide, and a set of metabolic and bone findings we did not anticipate. This application secures an early filing date for that work while we pursue it.”

ART27.13 is a peripherally restricted dual cannabinoid CB₁ and CB₂ receptor agonist. The Company believes the findings are particularly novel because historical research into cannabinoid signaling for obesity has largely focused on CB₁ antagonism. ART27.13 had no observed effect on any measured parameter in lean animals maintained on standard chow, a pattern Artelo believes is consistent with a metabolic regulator profile. Artelo plans to investigate the mechanisms behind these effects, including ART27.13’s potential impact on key pathways and hormones involved in appetite and metabolic regulation.

Rather than competing with GLP-1 therapies, ART27.13 is being evaluated as a potential complement to them, with the aim of improving both the magnitude and the quality of weight loss. ART27.13 enters obesity research with an existing clinical dataset: six completed clinical studies, two ongoing clinical trials, and nearly 300 participants receiving ART27.13 to date.

“Bone and lean mass are drawing growing attention as GLP-1 therapies are used more widely, so seeing bone mineral density increase in the combination group was notable,” added Mr. Gorgas. “The potential to enhance an established GLP-1 therapy while showing meaningful activity as a monotherapy is expected to create a new development path for ART27.13, and we intend to protect it as the science advances.”

About ART27.13

Initially developed by AstraZeneca plc, ART27.13 is a dual cannabinoid agonist that has been evaluated in six clinical studies and two ongoing clinical trials with nearly 300 participants. It is being developed as a once-daily oral agent that selectively targets peripheral CB₁ and CB₂ receptors, enabling systemic metabolic effects while minimizing central nervous system-mediated toxicity.

Artelo is conducting a Phase 2 trial, the Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 as a supportive care therapy for cancer patients with anorexia and weight loss. Patients had to have lost at least 5% of body weight to enroll. In interim data, those titrated to the highest dose (1300 µg) gained an average of 6% of body weight over 12 weeks, while patients on placebo lost an additional ~5%. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. ART27.13 is also being evaluated in DREAM, a Phase 2 study in people with glaucoma investigating whether oral daily treatment can lower intraocular pressure.

About the Diet-Induced Obesity (DIO) Model

The DIO-2 study evaluated ART27.13 in mice with diet-induced obesity, the standard nonclinical model used across the industry to evaluate GLP-1 receptor agonists and other anti-obesity therapies. Obese mice maintained on a high-fat diet were treated with vehicle, semaglutide (20 nmol/kg) s.c., ART27.13 (2.5 µmol/kg) orally, or semaglutide in combination with ART27.13 under three dosing regimens. Lean mice maintained on standard chow were treated with vehicle or ART27.13 to assess effects in non-obese animals. Body weight and food consumption were measured throughout the four-week treatment period, and body composition was assessed by DEXA and MRI imaging. The findings replicate and extend the results of an initial pilot study (DIO-1) in the same model, in which co-treatment with ART27.13 was observed to improve the weight-loss efficacy when used in combination with semaglutide.

Ozempic^® and Wegovy^® are registered trademarks of Novo Nordisk A/S. Artelo Biosciences is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the preliminary nature of the study results described in this press release, which remain subject to completion of the full analysis; the early stage of our obesity research program; the uncertainty of patent protection and the potential for intellectual property challenges; the fact that a provisional patent application does not itself result in an issued patent, confers no enforceable rights, and must be followed by a non-provisional application within 12 months to preserve its priority date; the highly competitive nature of the pharmaceutical industry, including the GLP-1, obesity and combination therapy markets; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company”) (CSE: BRU) (FSE: ZI3) is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (“FSE”) under the symbol “ZI3”, WKN: A42M2A and ISIN: CA1169151091.

The Company’s common shares are now cross-listed on the Canadian Securities Exchange and on the FSE, providing international exposure to both Canadian and European investors. The Company’s FSE stock quote link can be found here: https://live.deutsche-boerse.com/equity/bru-mng-inc-o-n?mic=XFRA

Christos Doulis, Chief Executive Officer of Brutus Mining, commented, “Germany has a long-established investor base for junior copper and gold exploration. The FSE listing puts Brutus in front of it as we begin work at the CW Property. CW is a road-accessible copper-gold project in British Columbia, with five documented mineral occurrences across a single contiguous land package.”

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU | FSE: ZI3) is a Vancouver-based mineral exploration company. Its sole asset is an option to acquire a 100% interest in the CW Property, five contiguous mineral claims totalling 2,894.56 hectares in the Kamloops Mining Division of south-central British Columbia, approximately 100 kilometres north of Kamloops. The Property hosts five documented MINFILE mineral occurrences with copper and gold mineralization and is at an early stage of exploration.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
Telephone: +1 (604) 636-7335
Email: info@brutusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the potential benefits of listing on the FSE. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

COLDWATER, Mich., Sept. 23, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Southern Michigan Bancorp, Inc. (OTC Pink: SOMC) declared a quarterly dividend of $0.17 per share on the outstanding shares of the corporation’s stock. The dividend is payable on October 16, 2026, to shareholders of record October 5, 2026. The annualized cash dividend of $0.68 per share represents a 2.19% dividend yield based on the current market price of $31.00 per share.

Southern Michigan Bancorp, Inc. is a bank holding company and the parent company of Southern Michigan Bank & Trust. It operates 18 offices within Branch, Calhoun, Hillsdale, Jackson, Kalamazoo, and St. Joseph Counties providing a broad range of consumer, business, and wealth management services throughout the region. For more information, please visit the Southern Michigan Bank & Trust website, www.smb-t.com. 

This press release contains forward-looking statements that are based on management’s beliefs, assumptions, current expectations, estimates and projections about the financial services industry, the economy, and Southern Michigan Bancorp, Inc. Although we currently expect to continue to pay a quarterly cash dividend, each future dividend will be considered and declared by the board of directors in its discretion. Whether the board of directors continues to declare dividends depends on a number of factors, including our future financial condition and profitability. Forward-looking statements are based upon current beliefs and expectations and involve substantial risks, uncertainties, and assumptions (“risk factors”), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. We undertake no obligation to update or revise our forward-looking statements to reflect developments that occur, or information obtained after the date of this report.

CONTACT: CONTACT: 
John Waldron, President & CEO
(517) 279-5500

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone 

Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026

CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide in adults living with obesity.

“This combination trial of WVE-007 with weekly tirzepatide marks an important milestone in our development plan to advance WVE-007 across three distinct obesity treatment settings: monotherapy, combination therapy, and as a post-incretin maintenance therapy to prevent weight recurrence,” said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. “Our preclinical data, as well as emerging clinical data in the field, support the potential for enhanced fat loss and preservation of muscle with WVE-007 as compared to incretins alone. The consequence of muscle loss is particularly important since beyond strength, skeletal muscle also plays an important role in both metabolism and weight maintenance. In our clinical data to date, we have demonstrated a differentiated profile for WVE-007, with potential for best-in-class INHBE silencing, favorable safety and tolerability, and once- or twice-yearly dosing.”

The INLIGHT™ clinical program is evaluating WVE-007 as a monotherapy and in combination with tirzepatide as a treatment for obesity and other cardiometabolic indications, including MASH. The placebo-controlled (3:1) Phase 2a combination trial will evaluate 240 mg and 400 mg doses of WVE-007 in combination with weekly tirzepatide in individuals living with obesity (BMI 35-50 kg/m²) and type 2 diabetes. The INLIGHT™ clinical program also includes an ongoing Phase 2a monotherapy trial, which includes multiple assessments over a 12-month period, and these results will inform further development of WVE-007 in obesity, as well as MASH, type 2 diabetes, and cardiovascular disease.

Wave also remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss following discontinuation of incretin treatment in the second half of 2026.

Wave previously presented preclinical data at ObesityWeek® 2025 demonstrating that WVE-007 has potential for use synergistically with GLP-1s as well as to curtail weight regain after the cessation of treatment with GLP-1.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and/or completion of our INLIGHT clinical trial and the timing and announcement of such events; our expectations to initiate new clinical trials evaluating WVE-007 for post-incretin maintenance, and the expected results and timing thereof; the potential of WVE-007’s mechanism (INHBE GalNAc-siRNA) as a meaningful and differentiated therapeutic approach for obesity as well as the potential to develop WVE-007 for other indications, including MASH, type 2 diabetes, and cardiovascular disease; the future performance and results of WVE-007 in the Phase 2a portions of our INLIGHT clinical trial, including our expectations that there will be even greater improvements in body composition in individuals with higher BMI, visceral fat and body fat at baseline; the potential benefits of our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), compared to others; the benefits of RNA medicines generally; and the potential for certain of our programs to be best-in-class. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce that its board of directors has approved a consolidation (the “Consolidation”) of the common shares of the Company (“Common Shares”) on a ten-to-one basis. The Company has 94,248,477 Common Shares outstanding and, if completed, the proposed Consolidation would reduce the issued and outstanding Common Shares to approximately 9,424,844 Common Shares.

The Company will issue a subsequent news release, following its filing of all necessary documentation with the Canadian Securities Exchange (“CSE”) in respect of the proposed Consolidation, announcing the effective date of the proposed Consolidation, the new CUSIP and ISIN for the consolidated Common Shares and any other relevant details regarding the proposed Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional shares resulting from the Consolidation will be rounded down to the next whole Common Share, and no cash consideration will be paid in respect of fractional shares.

The Company’s board of directors believes that the Consolidation will provide the Company with greater flexibility for the continued development of its business and the growth of the Company, including financing arrangements. There is no change of business associated or being effected with respect of the Consolidation. In addition, the Company will not be changing its name or stock symbol during the Consolidation.

About Aventis Energy Inc.

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the proposed Consolidation, including the proposed consolidation ratio, the anticipated effective date of the Consolidation and the anticipated effect of the Consolidation on trading in the Common Shares. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

Ellis Jacob to Serve as Special Advisor to the Board

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex Inc. (“Cineplex” or the “Company”), Canada’s leading entertainment and media company, announces the appointment of Bill Walker as Chief Executive Officer, effective today, following a comprehensive Board-led succession process initiated after the announcement last year that Ellis Jacob would retire from Cineplex.

The Company also announced that its board of directors (the “Board”) has initiated a review of strategic alternatives (the “Strategic Review”) to evaluate opportunities to enhance and maximize value for all shareholders.

To support a seamless leadership transition and the Strategic Review process, Ellis Jacob will serve as Special Advisor to the Board through December 31, 2026, working closely with the Board, management team and the Company’s advisors in connection with the review and assessment of strategic alternatives available to the Company.

Appointment of Bill Walker as Chief Executive Officer
After a robust and well-governed succession process that included both an extensive global search and consideration of internal candidates, the Board selected Bill Walker to lead Cineplex.

Walker is a highly respected retail and entertainment executive with extensive leadership experience across the cinema exhibition, real estate and retail sectors. He previously served as Chief Executive Officer of Landmark Cinemas, Canada’s second-largest theatre exhibitor, operating as part of Kinepolis Group NV (“Kinepolis”), a publicly traded cinema company based in Belgium.

During his nine-year tenure at Landmark, Walker established a strong track record of disciplined capital allocation, operational excellence and guest experience innovation. He also played a key leadership role in Landmark’s successful sale to Kinepolis in 2017 and subsequently continued to lead the Canadian business under Kinepolis’ public company ownership. He is widely known throughout the Canadian exhibition industry and has developed long-standing relationships with exhibitors, distributors and business partners across North America.

“The Board’s responsibility is to ensure that Cineplex is positioned to create long-term value for shareholders,” said Phyllis Yaffe, Chair of the Board of Cineplex. “Following a comprehensive succession process, we are delighted to appoint Bill Walker as the Company’s next Chief Executive Officer. Bill brings a unique combination of industry expertise, operational leadership, transaction experience and strategic perspective. Given his deep understanding of the theatrical exhibition industry and proven leadership experience, the Board is confident that Bill is exceptionally well positioned to lead Cineplex. At the same time, the Board believes it is appropriate to conduct a comprehensive review of strategic alternatives available to the Company. The appointment of Bill and the commencement of this review will provide the Company with leadership continuity and strategic flexibility to ensure shareholders benefit from the Company’s full potential.”

“I am honoured to join Cineplex at this important time in the Company’s history,” said Walker. “Cineplex is one of Canada’s most recognized and admired consumer brands, supported by outstanding employees and industry-leading assets. Throughout the recruitment process, I became increasingly excited about the Company’s future prospects and the opportunity to help lead its next chapter. Having spent much of my career in the exhibition industry, I have great respect for what the Cineplex team has built. I believe the Company possesses an exceptional platform for growth, a powerful brand and meaningful opportunities to create value. I fully support the Board’s commitment to evaluating strategic alternatives and look forward to working closely with the Board, management team and other stakeholders as the Strategic Review progresses. Regardless of the outcome of the Strategic Review, my focus will be on driving operational excellence, delivering exceptional guest experiences and superior outcomes for shareholders.”

Board Commences Strategic Review
The Board has initiated a Strategic Review to evaluate opportunities to enhance and maximize value for all shareholders. As part of the Strategic Review, the Board will consider a range of alternatives, including, but not limited to, a potential sale of the Company. 

The Board has engaged Goldman Sachs and TD Securities as co-financial advisors in connection with the Strategic Review. The Company has also retained Goodmans LLP as legal counsel.

The Strategic Review will be conducted under the oversight of the Board, working closely with Ellis Jacob in his capacity as Special Advisor to the Board, and with the assistance of the Company’s financial and legal advisors and senior management.

“The Board recognizes its responsibility to continuously evaluate opportunities to enhance shareholder value,” said Yaffe. “Cineplex has a strong market position, a portfolio of leading entertainment assets, powerful consumer brands, and attractive long-term growth opportunities. However, we believe the Company’s current market valuation may not fully reflect the strength of its business and long-term prospects. While we remain highly confident in the Company’s future prospects, we are committed to evaluating all available opportunities and remain open-minded regarding potential outcomes.”

The Board and management team remain committed to executing the Company’s strategic priorities and continuing to grow the business while the Strategic Review is underway. Cineplex remains focused on serving its guests, investing in its businesses and delivering long-term value for shareholders. 

No decisions have been made regarding any particular strategic alternative, and no timetable has been established for completion of the Strategic Review. There can be no assurance that the Strategic Review will result in any transaction, agreement or other strategic outcome. The Company does not intend to disclose developments relating to the Strategic Review unless and until it determines that disclosure is appropriate or required under applicable securities laws.

Ellis Jacob to Continue as Special Advisor to the Board
To support both the leadership transition and the Strategic Review, Ellis Jacob will remain actively involved with the Company through December 31, 2026 as Special Advisor to the Board. In this capacity, he will provide strategic counsel to the Board and assist in the evaluation of strategic alternatives available to the Company.

Jacob has served as President and Chief Executive Officer of Cineplex and its predecessor organizations for more than three decades and has played a central role in building Cineplex into Canada’s leading entertainment and media company.

“On behalf of the Board, I would like to thank Ellis for his extraordinary leadership, entrepreneurial vision and unwavering commitment to Cineplex,” said Yaffe. “Given his unparalleled knowledge of the business, longstanding industry relationships and exceptional track record of value creation, the Board believes Ellis’ continued involvement will be highly valuable as we advance both the leadership transition and the Strategic Review and work toward achieving the best possible outcome for shareholders.”

“It has been a privilege to lead Cineplex and work alongside the exceptional people who have helped build this Company over many years,” said Jacob. “I support the Board’s appointment of Bill Walker and its decision to undertake a comprehensive review of strategic alternatives. Cineplex has built an incredible portfolio of assets, a diversified business model, market-leading brands and strong stakeholder relationships. I look forward to continuing to work closely with the Board and our advisors as we evaluate opportunities to unlock value for shareholders.”

Cineplex
Cineplex (TSX:CGX) is a top-tier Canadian brand that operates in the Film Entertainment and Content, Amusement and Leisure, and Media sectors. Cineplex offers a unique escape from the everyday to millions of guests through its circuit of 168 movie theatres and location-based entertainment venues. In addition to being Canada’s largest and most innovative film exhibitor, the Company operates Canada’s favourite destination for ‘Eats & Entertainment’ (The Rec Room), complexes specially designed for teens and families (Playdium), and an entertainment concept that brings movies, amusement gaming, dining, and live performances together under one roof (Cineplex Junxion). It also operates successful businesses in cinema media (Cineplex Media), alternative programming (Cineplex Events) and motion picture distribution (Cineplex Pictures). Providing even more value for its guests, Cineplex is a partner in Scene+, Canada’s largest entertainment and lifestyle loyalty program.

Proudly recognized as having one of the country’s Most Admired Corporate Cultures, Cineplex employs over 10,000 people in its offices and venues across Canada. To learn more, visit Cineplex.com.

Caution Regarding Forward-Looking Statements
Certain statements and/or information in this news release (identified by words such as “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof)), and words and expressions of similar import, and similar expressions suggesting future events or future performance are intended to identify forward-looking statements. Such forward-looking statements are based on expectations and assumptions made by Cineplex and are subject to risks and uncertainties which may be beyond Cineplex’s control. Specifically, statements with respect to the Company’s current expectations regarding the Strategic Review are forward-looking statements.  There can be no assurance that the Strategic Review will result in any transaction, agreement or other strategic outcome.  A comprehensive discussion of risks that may impact Cineplex can be found in Cineplex’s public reports and filings, including those described in Cineplex’s Annual Information Form (“AIF”), and Management’s Discussion and Analysis for the year ended December 31, 2025 (“Annual MD&A”), which are both available under the Company’s profile on Sedar+ (www.sedarplus.ca). The foregoing list of factors that may affect future operations and results is not exhaustive. Readers are cautioned that undue reliance should not be placed on forward-looking statements as actual operations and results may vary materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. Cineplex does not undertake to update, correct or revise any forward-looking statements as a result of any new information, future events or otherwise, except as may be required by applicable law.

Investors:
Mahsa Rejali
Vice President, Corporate Development and Investor Relations
InvestorRelations@Cineplex.com

Media:
Michelle Saba, CPIR
Vice President, Communications
PressRoom@Cineplex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b811234-75dc-4b65-90ab-17dad6b7cdf8